<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781625</url>
  </required_header>
  <id_info>
    <org_study_id>S-08458d (REK)</org_study_id>
    <secondary_id>08/7922(Shdir)</secondary_id>
    <nct_id>NCT00781625</nct_id>
  </id_info>
  <brief_title>Probiotics as a Prophylactic Aid in Women With Recurrent Urinary Tract Infections (UTI's)</brief_title>
  <official_title>Probiotics/Lactobacillus as a Prophylactic Aid in Recurrent Bacterial Cystitis in Women. A Randomized, Prospective, Double-Blinded, Placebo Controlled, Multi-Center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Folkehelsa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if administration of probiotics, either orally or vaginally,

        -  Can reduce the number of episodes of acute bacterial cystitis and/or

        -  Has tolerable adverse effect profile

        -  Improves general QoL in these women

        -  Improves the immune function and other physiological stress markers

        -  Reduces inflammation in urinary bladder epithelium
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic recurrent bacterial cystitis is a condition that is disabling to a great extent and
      which influences quality of life and freedom of movement. The episodes can be painful, and
      lead to extensive use of antibiotics, which in itself promotes development of bacterial
      strains increasingly resistant to antibiotics, but do not prevent relapses. Almost all
      cystitis' in women are ascending infections from bacteria in the vagina, following
      colonization from the rectum. There have, however, been reported indications that there may
      be bacteria colonies within the urothelium that might give rise to relapses of the
      infections, rather than pure reinfection from ascending pathogens.

      Probiotics are cultures of viable microorganisms, which show a positive effect on the general
      condition of the host when administered. Among the lactic acid bacteria (LAB), lactobacilli
      are the most commonly used for probiotics, and they have an excellent safety record. In terms
      of UTI, weekly or twice weekly intravaginal instillation of Lactobacillus strains GR-1 and
      B-54 have led to reduced recurrences. This concept has been supported by a 2006 pilot study
      showing that intravaginal administration of Lactobacillus crispatus GAI 98322 every two days
      for one year, had the potential to reduce the UTI recurrences. Another approach has been
      taken whereby lactobacilli are administered orally with a view of simulating how the
      pathogens reach the vagina. The studies have shown that L. rhamnosus GR-1 and L. reuteri
      (formerly fermentum) RC-14 can reach the vagina after daily oral ingestion, and they can
      lower the bacterial and yeast pathogen numbers.

      The aim of the study is to try to normalize the vaginal bacteriological milieu so that the
      more pathogenic subpopulation of bacteria strains are displaced and are less likely to cause
      UTI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in number og episodes og lower UTI</measure>
    <time_frame>6 months intervention period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of QOL</measure>
    <time_frame>6 months intervention period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of immune function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects are non-dependant og nutritional status</measure>
    <time_frame>6 month2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects are non-dependant of known factors contributing til UTI's</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreases inflammation in the urinary bladder epithelium</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalizes vaginal microflora</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Probiotic vaginal capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic vaginal capsule, placebo oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo oral capsule, placebo vaginal capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic oral capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic oral capsules, placebo vaginal capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>UREX-cap-5</intervention_name>
    <description>Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.</description>
    <arm_group_label>Probiotic oral capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>UREX-cap-5</intervention_name>
    <description>Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.</description>
    <arm_group_label>Probiotic vaginal capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Y cap G-3</intervention_name>
    <description>Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women 18-70 years old

          -  spontaneous urination

          -  &gt; 3 UTI's previous year

          -  no ongoing prophylactic antibiotic treatment

        Exclusion Criteria:

          -  &gt; 50 ml residual urine

          -  neurological bladder disease

          -  known neoplasia, kidney stone or urinary tract abnormalities

          -  use og indwelling catheter

          -  pregnancy

          -  diabetes

          -  infrequent voiding pattern

          -  symptoms that indicate interstitial cystitis

          -  creatinin &gt; 250 micmol/L

          -  participating in other clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline U Skagemo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akershus Universitetssykehus HF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunn Iren Meling, PhD. MD</last_name>
    <role>Study Director</role>
    <affiliation>Akershus Universitetssykehus HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Ursin Skagemo, MD</last_name>
    <phone>+47 02900111</phone>
    <email>cask@ahus.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunn Iren Meling, PhD, MD</last_name>
    <phone>+47 02900111</phone>
    <phone_ext>69298</phone_ext>
    <email>gmel@ahus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus Universitetssykehus HF</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline U Skagemo, MD</last_name>
      <phone>+47 02900111</phone>
      <email>cask@ahus.no</email>
    </contact>
    <contact_backup>
      <last_name>Gunn Iren Meling, PhD, MD</last_name>
      <phone>+47 02900 111</phone>
      <email>gmel@ahus.no</email>
    </contact_backup>
    <investigator>
      <last_name>Caroline U Skagemo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>October 29, 2008</last_update_submitted>
  <last_update_submitted_qc>October 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>MD Caroline Ursin Skagemo</name_title>
    <organization>Urologisk avdeling, Akershus Universitetssykehus HF</organization>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>QoL</keyword>
  <keyword>inflammation</keyword>
  <keyword>nutritional factors</keyword>
  <keyword>prophylactic aid</keyword>
  <keyword>Lactobacillus rhamnosus GR-1</keyword>
  <keyword>Lactobacillus reuteri RC-14</keyword>
  <keyword>Recurrent lower UTI in women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Titanium dioxide</mesh_term>
    <mesh_term>Methenamine hippurate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

